Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease

Summary

Subjects in whom a posterolateral fusion surgery has been planned and who meet the inclusion and exclusion criteria were proposed to receive a single-dose AMSC treatment, in order to assess its safety and efficacy on posterolateral interbody fusion. After the surgery, the subjects were followed up as out-patients during 5 study visits for 12 months in total.

Timeline

Start

2013-08-27

Primary completion

2016-12-14

Completion

2016-12-14

Outcome

Outcome not reported

Stopped: “Primary endpoint (Safety) has been achieved”

Drugs

Indications